Identification of miR-379/miR-656 (C14MC) cluster downregulation and associated epigenetic and transcription regulatory mechanism in oligodendrogliomas by Kumar, A et al.
Identification of miR­379/miR­656 
(C14MC) cluster downregulation and 
associated epigenetic and transcription 
regulatory mechanism in 
oligodendrogliomas
Kumar, A, Nayak, S, Pathak, P, Purkait, S, Malgulawar, PB, Sharma, MC, Suri, V, 
Mukhopadhyay, A, Suri, A and Sarkar, C
http://dx.doi.org/10.1007/s11060­018­2840­6
Title Identification of miR­379/miR­656 (C14MC) cluster downregulation and 
associated epigenetic and transcription regulatory mechanism in 
oligodendrogliomas
Authors Kumar, A, Nayak, S, Pathak, P, Purkait, S, Malgulawar, PB, Sharma, MC, 
Suri, V, Mukhopadhyay, A, Suri, A and Sarkar, C
Type Article
URL This version is available at: http://usir.salford.ac.uk/47497/
Published Date 2018
USIR is a digital collection of the research output of the University of Salford. Where copyright 
permits, full text material held in the repository is made freely available online and can be read, 
downloaded and copied for non­commercial private study or research purposes. Please check the 
manuscript for any further copyright restrictions.
For more information, including our policy and submission procedure, please
contact the Repository Team at: usir@salford.ac.uk.
Vol.:(0123456789) 
Journal of Neuro-Oncology 
https://doi.org/10.1007/s11060-018-2840-6
LABORATORY INVESTIGATION
Identification of miR-379/miR-656 (C14MC) cluster downregulation 
and associated epigenetic and transcription regulatory mechanism 
in oligodendrogliomas
Anupam Kumar1,2 · Subhashree Nayak2 · Pankaj Pathak2 · Suvendu Purkait2 · Prit Benny Malgulawar2 · 
Mehar Chand Sharma2 · Vaishali Suri2 · Arijit Mukhopadhyay3,4 · Ashish Suri1 · Chitra Sarkar2 
Received: 22 December 2017 / Accepted: 20 March 2018 
© The Author(s) 2018
Abstract
Introduction Although role of individual microRNAs (miRNAs) in the pathogenesis of gliomas has been well studied, their 
role as a clustered remains unexplored in gliomas.
Methods In this study, we performed the expression analysis of miR-379/miR-656 miRNA-cluster (C14MC) in oligoden-
drogliomas (ODGs) and also investigated the mechanism underlying modulation of this cluster.
Results We identified significant downregulation of majority of the miRNAs from this cluster in ODGs. Further data from 
The Cancer Genome Atlas (TCGA) also confirmed the global downregulation of C14MC. Furthermore, we observed that its 
regulation is maintained by transcription factor MEF2. In addition, epigenetic machinery involving DNA and histone-meth-
ylation are also involved in its regulation, which is acting independently or in synergy. The post- transcriptionally regulatory 
network of this cluster showed enrichment of key cancer-related biological processes such as cell adhesion and migration. 
Also, there was enrichment of several cancer related pathways viz PIK3 signaling pathway and glioma pathways. Survival 
analysis demonstrated association of C14MC (miR-487b and miR-409-3p) with poor progression free survival in ODGs.
Conclusion Our work demonstrates tumor-suppressive role of C14MC and its role in pathogenesis of ODGs and therefore 
could be relevant for the development of new therapeutic strategies.
Keywords miRNA cluster · C14MC · MEG3 · MEF2 · Oligodendrogliomas
Introduction
Oligodendroglioma (ODG) accounts for 5–9% of all glio-
mas [1] (CBTRUS statistical report: NPCR and SEER; 
2006–2010) and is classified by World Health Organiza-
tion (WHO, 2016) into IDH1 mutant and 1p/19q co-deleted 
grade II and IDH1 mutant and 1p/19q co-deleted anaplastic 
grade III ODGs [2]. Emerging evidences suggest significant 
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role of dysregulated microRNAs (miRNAs) in the pathogen-
esis of cancers. MiRNAs have been established as critical 
players in tumor progression and potent candidates in the 
advancement of cancer diagnostics and therapeutics [3, 4]. 
These short non-coding RNA molecules usually negatively 
regulate the translation of target mRNA by binding to their 
3′untranslated region (3′UTR) [5]. Due to its short length 
and imperfect base-pairing, an individual miRNA is pre-
dicted to have hundreds of target mRNAs. Conversely, sev-
eral miRNAs are grouped in cluster and regulate a single tar-
get. Studies accumulated in recent pasts have identified the 
complex role of miRNA clusters transcribed in the human 
genome and several reports have linked clustered miRNAs 
to variety of cancers, in which these shown to act like either 
oncogenes or tumor suppressors [6]. Though there are few 
reports demonstrating the role of individual miRNAs in 
pathogenesis of ODGs are well documented [7, 8] however, 
the contribution of clustered miRNAs remains unexplored.
miR-379/miR-656 cluster [hereafter named as C14MC], 
one of the largest miRNA clusters, is located within an 
imprinted chromosomal region DLK1(delta-like homolog 
1)—DIO3(iodothyronine deiodinase 3) on chromosome 
14q32.31 region and harbors distinct imprinted genes 
(DLK1, RTL1, MEG3, MEG8 and DIO3), C/D small nucle-
olar RNAs (SNORDs) and more than 50 miRNA genes [9, 
10]. The polycistronic nature of this cluster has been shown 
to be under positive regulation of Mef2 transcription factor 
in rat neurons [11].
Several studies have documented dysregulation of this 
cluster in various cancers such as melanoma, ependymoma, 
medulloblastoma, neuroblastoma and lung adenocarci-
noma [12–16]. However, its role in the oligodendroglio-
mas remains poorly understood. Therefore, in the present 
study, we analyzed the expression of several miRNAs from 
C14MC cluster and identified their downregulation in 
ODGs. In addition, we also investigated the possible func-
tional mechanism for its downregulation. Our study showed 
that transcription factor MEF2, along with epigenetic 
machinery involving hypermethylation of the cluster locus 
and enrichment of H3K27me3 mark at the regulatory region 
could be the underlying mechanism for the downregulation 
of this cluster which either acts independently or in synergy. 
Further downregulation of this cluster also showed prognos-
tic significance in ODGs.
Materials and methods
Patient characteristics
The study included 43 cases of oligodendroglioma show-
ing classical histology and also fulling recent WHO 2016 
classification by showing co-deletion of 1p/19q and IDH/2 
mutations and retained ATRX expression. There were 23 
cases of Grade II (MIB1-1 to 12%) and 20 cases of grade III 
(MIB1-5 to 28%) with mean age of 40 years ranging from 
26 to 65 years with M:F ratio of 3.4:1. A summary of the 
clinical features is shown in Supplementary Table S1.
Nucleic acid isolation
Total DNA and RNA from frozen tumor and control tis-
sues were extracted using Qiagen mini DNA prep (Qiagen, 
Germany) and mirVana total RNA isolation Kit (Ambion, 
USA), respectively, following the manufacturer’s instruc-
tions. Concentration and purity of the total DNA and RNA 
samples were measured using the Picodrop Microliter UV/
Vis Spectrophotometer (Picodrop Limited, UK) and gel 
electrophoresis.
Analysis of co‑deletion of 1p/19q, IDH1 mutation
Co-deletion of 1p/19q in all the ODGs was assessed by dual-
probe fluorescence in situ hybridization (FISH) assay as per 
our standard protocol described before [17]. Mutations in 
exon 4 of IDH1 gene was determined using direct bidirec-
tional sequencing as described before [17], Supplementary 
Table S2.
C14MC expression profiling by TLDA
miRNA profiling for the C14MC microRNA cluster was per-
formed using customized TaqMan low density array (TLDA) 
microfluidic cards (Applied Biosystems, CA) as described 
earlier [23]. Details of the candidate miRNAs and endog-
enous controls found on TLDA cards are provided in Supple-
mentary Table S3. Threshold cycle (Ct) values greater than 
35 were imputed to 35 according to the technical recommen-
dation [24]. The Ct was calculated by relative quantification 
using  2−∆∆Ct method [18].
C14MC expression analysis using TCGA data
Genome-wide small RNA sequencing level 3 data (calcu-
lated expression for all reads aligning to a particular miR, 
per sample) for 153 ODGs samples (Grade II-64, Grade III-
89) and 5 controls was extracted from The Cancer Genome 
Atlas (TCGA) and was analyzed for differentially expressed 
miRNAs from C14MC cluster. Differential expression 
analysis was performed using non-parametric two-tailed 
Mann–Whitney U test and corrected for multiple compari-
sons by Bonferroni correction [19].
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cDNA conversion and RT‑PCR based gene expression 
analysis
Expression of all the genes and miRNAs of interest were 
studied by real-time RT-PCR. 10 ηg of cDNA was used 
for qPCR reaction for all the genes of interest SnU6 and 
GAPDH were used as endogenous control for miRNA and 
mRNA, respectively. The primer sequences of the genes and 
miRNAs are listed in Supplementary Table S2. The Ct was 
calculated by relative quantification using  2−∆∆Ct method 
[18].
Cell culture and 5‑azacytidine treatment
Oligodendroglioma cell line HS683 [20] was obtained 
from ATCC (HTB-138™) and cultured in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 
10% fetal calf serum, 0.2 mM glutamine and antibiotics 
(50 µg/ml penicillin, 50 µg/ml streptomycin) and incubated 
at 37 °C in an atmosphere containing 5%  CO2. For drug 
treatment cells were seeded at a density of 5 × 105 cells per 
well in six-well plate and treated 5-azacytidine (Sigma, 
USA) at a concentration of 5 µM and the medium was 
replenished every 24 h until the 72-h treatment was com-
pleted. Expression of miRNAs and MEG3 was analyzed 
using qRT-PCR.
Chromatin immunoprecipitation (ChIP)‑qPCR
ChIP assays were performed using the Low Cell ChIP 
Kit (M/S Diagenode, Belgium) protocol with some minor 
modifications. Briefly, cell pellets were collected and 
cross-linked using 1% formaldehyde in PBS and reaction 
was stopped using 100 µl of 125 mM glycine. The chroma-
tin was fragmented using Bioruptor plus (M/S Diagenode, 
Belgium) and fragmented chromatin (equivalent to 1 mil-
lion cells) was immunoprecipitated using anti-MEF2A 
antibody (M/s Abcam, USA), anti-H3K27me3 antibody 
(M/s Abcam, USA), anti-IgG Mouse (M/s Abcam, USA) 
and Rabbit antibody (M/s Abcam, USA) as per Low Cell 
ChIP kit guidelines. After overnight incubation, the aga-
rose beads were washed and immunoprecipitated and input 
DNA was processed for DNA isolation using IPure kit 
(M/s Diagenode, Belgium) following the manufacturer’s 
instructions. The precipitated DNA fractions were quan-
tified by real-time RT-PCR using SYBR Green dye with 
primers encompassing binding site region of MEF2A, 
MEG3 and GAPDH (negative control). The primer 
sequences are listed in Supplementary Table S2. Target 
enrichment was expressed as the percent input by using the 
following formula: Percentage of total input = 100 × 2^[Ct 
(ChIP)–(Ct input–log2 (input dilution factor))] [21].
Methylation status analysis of C14MC
Genome wide methylation data generated on Infinium 
HumanMethylation450K BeadChip (Illumina Inc.) was 
obtained for 156 ODG cases from TCGA data portal and 
analysis was done as described previously [19]. Methyla-
tion status of MEG3 promoter was tested using methyla-
tion-specific PCR primers designed for MEG3-DMR in 
ODGs. The primer sequences are listed in Supplementary 
Table S4.
Genome‑wide mRNA expression analysis
The mRNA expression profiles of 13 ODGs (6 Grade II, 7 
Grade III) and 3 normal brains were examined using Affy-
metrix Human 2.0 ST array (Affymetrix Inc, CA) as per the 
protocols outlined in detail in the geneChip@ expression 
analysis technical manual (Affymetrix, http://www.affym 
etrix .com/suppo rt/downl oads/manua ls/expre ssion _analy 
sis_techn ical_manua l.pdf). mRNA signal intensities were 
log2 transformed and analyzed for differentially expressed 
mRNAs using the Transcriptome Analysis Console (TAC) 
(Affymetrix Inc, CA) [22]. Differentially detected mRNA 
signals with ≥ 2.0 fold-change and the P < 0.05 were con-
sidered significant.
Survival analysis
The prognostic significance of miRNAs from C14MC 
cluster was analyzed using TCGA clinical dataset. Of the 
156 TCGA ODG samples, survival data was available for 
82 ODGs. The data was partitioned into two quantiles and 
Kaplan–Meier survival analysis was used to examine pro-
gression-free survival (PFS) and comparison was performed 
by log-rank test.
Statistical analysis and bioinformatic analysis
Statistical analysis was conducted with the SPSS software 
version 16.0 (SPSS, Inc., Chicago, IL, USA) for clinico-
pathological correlations. TCGA and REMBRANDNT 
dataset were used as an independent data set for experimen-
tal results validation on larger sample set. P-values < 0.05 
obtained using t-test were considered statistically significant.
Results and discussion
C14MC cluster are downregulated 
in oligodendrogliomas
Small RNA sequencing-based expression profile for miR-
NAs from C14MC cluster (n = 39) in 153 ODG samples (64 
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Grade III and 89 Grade II) revealed global downregulation 
of the miRNAs (37/39 miRNAs: ~ 94%) from this cluster. 
Further, RT-PCR based expression analysis of 47 miRNAs 
from C14MC cluster using TLDA assay also showed signifi-
cant downregulation of 40/47 miRNAs (Fold change < 0.6; 
p < 0.05) in ODG samples as compared to controls Fig. 1a, b. 
Majority (66%; 31/47) of the miRNAs were downregulated 
in more than 80% of the cases and Interestingly miR-329 was 
downregulated in all the cases analyzed.
On matching the TLDA and TCGA dataset, compara-
ble downregulation was seen in majority of the miRNAs 
(33/39; 84%), while discordance was seen only with 6/39 
(15%) miRNAs. Thus, downregulation of this cluster was 
established on two independent platforms and experimental 
setups in ODGs. Further, on comparing the expression of 
C14MC miRNA across the histological grades, we observed 
that 24% (11/47) of miRNAs (hsa-miR-154*, hsa-miR-544, 
hsa-miR-541, hsa-miR-409-5p, hsa-miR-329, hsa-miR-376b, 
hsa-miR-380-3p, hsa-miR-381, hsa-miR-654-3p, hsa-miR-
369-3p, hsa-miR-487a) each p < 0.01 were differentially 
expressed between the grade II and III (Fig. 1c). Notably, 
there was higher fold under expression of miRNAs in grade 
III as compared to grade II. Similar to our finding, Ludwing 
et al. also observed more fold downregulation of several 
miRNAs from C14MC in grade III meningioma as compared 
to grade II [23]. Thus, our findings indicate that C14MC 
might be contributing in tumor initiation in early phase in 
ODGs.
Regulation of C14MC expression
Since an orchestrated expression pattern for majority 
of miRNAs from C14MC throughout the samples was 
observed in ODGs, therefore, this further suggests either 
the existence of a polycystronic primary miRNA transcript 
or regulation of the C14MC by a common mechanism. 
Therefore, we investigated the underlying mechanism of 
C14MC downregulation. As genome level loss have been 
previously reported to regulate the expression of miR-
NAs [24] Therefore, we hypothesized that aberration of 
genomic region confined to C14MC could lead to their 
downregulation. Since, the miRNAs from C14MC are 
expressed only from the maternally inherited allele; dele-
tion of the active allele may result in complete silencing 
of this cluster. Therefore, we performed CytoScan 750K 
Array (Affymetrics, USA) in representative ODG patient 
samples and correlated the expression of C14MC with the 
presence of LOH of 14q32.31. However, we did not find 
Fig. 1  a The heat map shows the fold changes of miRNAs of 
C14MC in 43 ODGs with respect to normal brain using TLDA. Fold 
change ≤ 0.5 represents down-regulation (green), ≥ 2 upregulation 
(red) and > 0.5 to < 2 non-differential expression (Black). b Bar graph 
showing  homogenous down-regulation of C14MC in ODG samples 
as compared to controls. c Box plot showing differential expression 
C14MC between grade-II vs grade-III ODGs using TCGA data-
set. d Box plot shows expression levels of different MEF2 isoforms. 
“CTRL” and “ODG” represent controls and patient data, respectively. 
Significant downregulation was found for MEF2B and MEF2D. e The 
normalized expression values of each isoforms of MEF2 from REM-
BRANDANT dataset. Y-axis shows expression levels of different 
MEF2 isoforms in ODGs. f ChIP-qPCR showing binding of MEF2A 
to the MEF2 binding site (MEF2-BR) upstream of C14MC cluster 
using anti-Mef2A antibody and IgG as a control. MEF2A ChIP assay 
showed eightfold enrichment of MEF2A at the MEF2 binding region
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relevant changes in DNA copy number corresponding to 
the C14MC expression indicating that genomic loss is 
probably not responsible for reduced expression of this 
cluster in ODGs. This was further supported by the obser-
vation made by Lavon et al. where expression of miRNAs 
from the C14MC cluster was uniformly downregulated 
irrespective of the LOH status of 14q in GBM [25]. Hence, 
we propose that other mechanisms are likely responsible 
for silencing this cluster in ODGs.
Transcription factor MEF2 regulates C14MC 
expression
MEF2 has been implicated as regulatory transcription fac-
tor of C14MC cluster in rat neuron and muscle cells [11]. 
Therefore, we studied the expression of all its four isoforms: 
MEF2A, MEF2B, MEF2C and MEF2D by real time PCR 
and observed significant downregulation of MEF2A and 
MEF2D in ODGs (p < 0.00 for both). In addition, analysis 
of MEF2 expression using REMBRANDT dataset [26] also 
showed similar pattern of expression for MEF2 isoforms 
(Fig. 1d, e). Further, Since MEF2 expression correlated with 
C14MC expression therefore, we performed the ChIP–qPCR 
to confirm the binding of MEF2A on the MEF2 binding 
site (MBS) located upstream of the C14MC in HS683 cells. 
Our result showed approximately eightfold enrichment of 
bound chromatin compared with input confirming binding of 
MEF2A to the MEF2 binding site (MBS) suggesting MEF2 
as a positive regulator and as a controller of C14MC expres-
sion in ODGs (Fig. 1f).
C14MC genomic region showed hypermethylation 
in ODG
Several studies report hypermethylation mediated silencing 
of most of the miRNAs from this cluster in various tumors 
[24, 27, 28] therefore, we analysed the methylation status 
of genomic locus harbouring this cluster. On comparison 
of methylation status of C14 locus between tumor and nor-
mal brain samples (analyzed from GEO), most of the probes 
for the C14MC genomic region had a median beta value of 
> 0.8, thus indicating this region to be significantly hyper-
methylated (p < 0.002) Supplementary Table S4. Further, 
to exclude the possibility of hypermethylation of C14MC 
as a random event we analysed the methylation status of 
ten random genomic region and observed variable distribu-
tion of beta-values (normal range; 0.2–0.8) for those regions 
Fig. 2a, b which confirmed it not be a random event.
Furthermore, to substantiate the role of methylation for 
downregulation we treated HS683 cells with DNA-demeth-
ylating agent 5-azacytidine(5′-AZA) at 5 µM for 72 h and 
observed restored expression for few of the randomly tested 
miRNAs (miR-485-5p, miR-299-3p and miR-381: p < 0.05 
for each). However, some of the miRNAs tested (Mir-154, 
miR-487b, and miR-377) did not show change in its expres-
sion after treatment. Figure 2c These in vitro results suggest 
that along with DNA methylation, there exist other mecha-
nisms of transcriptional regulation and/or posttranscriptional 
modification that co-operate to control C14MC expression 
in ODGs.
Decreased expression of imprinted MEG3 gene 
mediates downregulation of C14MC
Our various aforementioned findings prompted us to con-
sider other epigenetic explanations for the observed silenc-
ing of C14MC in ODGs. As mentioned earlier, since MEG3 
and C14MC loci are in the same region therefore we studied 
the expression of MEG3 and correlated its expression with 
C14MC. Expression analysis of MEG3 using qRT-PCR 
and using REMBRANDT dataset showed its significant 
lower expression in ODG samples as compared to control 
(p < 0.05). Subsequently, we also observed significant corre-
lation between MEG3 and C14MC expression  (R2 = 0.46 and 
p = 0.001 using Pearson’s correlation coefficient) Fig. 2d, e.
Further, since MEG3-DMR is imprinting control center 
for the DLK1–DIO3 domain and it overlaps with the MEG3 
promoter therefore, methylation status of MEG3 promoter 
was tested using methylation-specific PCR. We observed 
aberrant methylation of MEG3 in 37% (11/30) of cases of 
which, methylated pattern was seen in 13%, partially meth-
ylated in 23% whereas 63% showed unmethylated pattern 
Fig. 2f. Further, to investigate the role of the promoter 
methylation in silencing the MEG3 gene, HS683 cells were 
treated with 5′-AZA at 5 µM for 72 h and showed a mini-
mal increase in the expression of MEG3 in treated group 
with respect to the control group suggesting involvement 
of some other mechanisms other than DNA methylation for 
the silencing of MEG3. Therefore, we considered histone 
modifications for the observed downregulation of MEG3. 
Since H3K27me3 is associated with repressive expression, 
we reasoned that presence of H3K27me3 at MEG3 promoter 
could be associated with its silencing effect. To confirm this, 
Chromatin Immunoprecipitation-qPCR was performed using 
H3K27me3 antibody on HS683 cells and ChIP-qPCR data 
analysis revealed enrichment of H3K27me3 (30 fold) at 
MEG3-DMR suggesting histone trimethylation mediated 
silencing of this gene (Fig. 2g). Thus, our results deliver 
a novel mechanistic relationship of H3K27me3 in mediat-
ing gene silencing effect for MEG3 DMR in ODGs as also 
observed in lung adenocarcinoma and urothelial carcinoma 
[29, 30].
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Post‑transcriptional regulatory network of C14MC 
in ODGs
miRNAs exert their roles either through inhibiting or by 
degrading target mRNAs translation. This makes the status 
of miRNA target genes as a fundamental step to understand 
their biological functions. Hence, we evaluated the post-
transcriptional regulatory network potentially regulated by 
C14MC miRNAs Insilco. For this we selected 43 down-
regulated miRNAs from the C14MC cluster and used the 
miRsystem webtool to search for predicted targets of each 
of these miRNAs. All the genes targeted by 43 miRNAs 
were included for Gene Set Enrichment Analysis (GSEA). 
Since the miRNAs from C14MC cluster showed downregu-
lation in ODGs therefore, we compared the list of potential 
targets of these miRNAs with microarray mRNA expres-
sion data generated using human ST array chip and searched 
for those showing significant upregulation (> 1.5-fold) in 
ODG samples. The resulting list of 170 predicted targets was 
subsequently submitted to the EnrichR webtool to identify 
enriched biological processes and signaling pathways. The 
most significantly enriched biological processes were glioma 
pathway, notch signaling pathway and phosphatidylinositol 
signaling pathway (P value < 0.001) (Fig. 3a, b). These path-
ways have also been reported to be involved in ODGs in pre-
vious studies suggesting the role of C14MC downregulation 
Fig. 2  a Hypermethylation of C14MC domain in ODG samples as 
compared to normal brain as controls. Infinium HumanMethylation 
450K BeadChip data (raw image files) from GEO (GSE43414) ana-
lysed using Minfi (Bioconductor package of R). Higher beta-values 
represent hypermethylation. b Relative methylation levels of the 
C14MC locus (~ 200 probes) are plotted along the vertical axis (beta 
values). The box plots determine the median beta-values of those 
regions. Ten random regions of the human genome (R1–R10) hav-
ing similar number of methylation probes as that of C14MC region 
is also plotted. C19MC (miRNA cluster present on Chr19) is plot-
ted as a control to test the specificity of the methylation pattern on 
C14MC in ODG. c Treatment with the epigenetic drugs Azacytidine 
(AZA) in HS683 cells showing re-expression of 3 miRNAs out of 6 
C14MC miRNAs tested. Represented data is relative to control cells 
which were set to 1. Average of three independent experiments with 
standard deviation (error bars) is shown. d Real-time PCR data show-
ing significant downregulation of MEG3 (p = 0.01) in ODGs versus 
ctrl. REMBRANDANT dataset shows the median expressions of 
MEG3 is distinctly lower in ODG than the control samples. e Scatter 
plot showing the significant correlation among the mean of miRNAs 
expression from C14MC cluster with MEG3 expression (R = 0.46 
and P = 0.001). f Methylation-specific PCR assay using primer set 
for the methylated (M) and unmethylated (U) copies of the MEG3 
DMR gene. Neg ctrl stands for the negative control (no DNA sam-
ple). Pos ctrl stands for methylated control which is universally meth-
ylated DNA. positive ctrl, ODG sample 1 and 3 were positive only for 
M. Samples ODG 2, 4 positive for partially methylated (M and U). 
A 160 bp PCR product represents the methylated state and a 120 bp 
PCR product stands for the unmethylated (L = 100  bp ladder, Invit-
rogen). g Chromatin immunoprecipitation (ChIP)-qPCR confirming 
enrichment of histone modifications at the promoter of the MEG3 
DMR. Results of quantitative reverse transcription polymerase chain 
reaction (RT-PCR) conducted using DNA after ChIP with antibody 
against H3K27me3 showed 30 fold enrichment of bound chromatin 
compared with input in HS683 cell line. GAPDH was used as a con-
trol
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in ODG pathogenesis by perturbing the tumorigenic and 
other biological processes [31, 32].
Downregulation of C14MC miRNAs are associated 
with poor PFS in ODGs
Several studies have shown a tumor suppressor role of sev-
eral downregulated miRNAs from C14MC by targeting key 
oncogenes in glioblastoma, pancreatic cancer, pulmonary 
cancer, glioneuronal tumors, metastatic lung cancer, has 
been well documented [33–36]. In contrast, miRNAs from 
the C14MC has been also reported to act as oncogenes as 
well [37] suggesting that these miRNAs may have differ-
ent biological roles depending on the tissue of origin and 
genetic background. However, our survival analysis using 
TCGA clinical dataset revealed an association of downreg-
ulation of this cluster with poor progression free survival 
(PFS) in ODGs. Further survival analysis of the in-house 
clinical dataset using Kaplan–Meier curve also demonstrated 
similar finding. Higher fold under expression of miR-409-3p 
(Median fold change = − 3; p = 0.04) and miR-487b (Median 
fold change = − 2.8; p = 0.04) showed association with 
shorter PFS in total ODGs (Fig. 3c, d). However, we did not 
find significant association of C14MC with PFS separately 
in grade II and grade III ODGs. Similar to our observation, 
lower expression of miR-487b and miRNA-409-3p has also 
been reported to correlate with poor prognosis in several 
other tumors [16, 33–36]. This finding signifies that the 
optimal expression of the whole miRNA cluster could be 
linked to better prognosis, hence, highlighting on the tumor 
suppressor potential of the same.
Conclusion
In conclusion, our work is the first to report the silencing 
of the second largest miRNA cluster in ODGs, importantly 
implicating its tumor-suppressive role in their pathogene-
sis. Dysregulation of the transcription factor (MEF2) along 
with epigenetic machinery involving DNA methylation 
and histone modifications could be the possible mecha-
nism for C14MC downregulation, acting independently or 
in synergy, in ODGs. Overall, our findings have uncovered 
another layer of regulatory network of downregulation of 
C14MC and have increased our basic understanding of the 
genetic and epigenetics mechanisms responsible for oligo-
dendroglioma genesis. However, future functional studies 
will shed additional light on the function of these miRNAs 
in ODG pathogenesis.
Fig. 3  a Venn diagram showing genes common between the pre-
dictive directs and gene expression analysis. b Signalling pathway 
affected by C14MC dysregulation in ODGs. c Representative sur-
vival plot of the association between C14MC expression and patient 
outcome in ODGs using TCGA clinical dataset. Blue represents low 
expression, whereas red represents higher expression X- axis is time 
in months. d Kaplan Meier survival curve for patients for miR-409-3p 
and 487b using log rank test (inhouse clinical dataset). Patients that 
had lower expression level of miR-409-3p and miR-487b showed 
poor PFS than those which had higher expression of miR-409-3p and 
miR-487b (p = 0.04) for both
 Journal of Neuro-Oncology
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